Early Insights into Biosimilar Cost Savings in the United States

A recent study inJAMA Oncologyexamined the average daily cost of  biosimilar filgrastim-sndz compared with the brand name biologic.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news